The goal of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium is to advance therapeutic development for sporadic and familial forms of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), primary lateral sclerosis (PLS), multisystem proteinopathy (MSP), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The CReATe consortium aims to support this goal through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.
The consortium includes sites at the University of Miami, Florida; the University of Kansas Medical Center; the University of California at San Diego; California Pacific Medical Center; the University of Tübingen, Germany; the University of Pennsylvania; the University of Texas Southwestern; the University of Texas Health Sciences Center San Antonio; the University of Iowa; Wake Forest University; Twin Cities ALS Consortium, Minnesota; and University of Cape Town, South Africa. The consortium is under the direction of Michael Benatar, MD, PhD, of the University of Miami.